Edwards Lifesciences (EW) – A Comprehensive Fundamentals Review

By Harris Dyer • Sunday, December 31 11:18 • Permanent Link

More and more people are talking about Edwards Lifesciences over the last few weeks. Is it worth buying the Specialty Industrial Machinery stock at a price of $76.25? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Edwards Lifesciences has moved 2.7% over the last year, and the S&P 500 logged a change of 24.7%
EW has an average analyst rating of buy and is -3.38% away from its mean target price of $78.92 per share
Its trailing earnings per share (EPS) is $2.34
Edwards Lifesciences has a trailing 12 month Price to Earnings (P/E) ratio of 32.6 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $2.77 and its forward P/E ratio is 27.5
The company has a Price to Book (P/B) ratio of 6.95 in contrast to the S&P 500's average ratio of 2.95
Edwards Lifesciences is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
EW has reported YOY quarterly earnings growth of 14.5% and gross profit margins of 0.8%
The company has a free cash flow of $889.96 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.